Member Info for Krone

EMA Website updated (11/9/2021) as below noting 'prematurely ended' (i.e. not actually started) i.r.o combination study of SRA737 with Niraparib.
"This study was prematurely terminated due to a change in the positioning of the clinical development pipeline for Sierra Oncology. The clinical trial was approved, but it was never started, no subjects were enrolled, and no clinical trial results are available".
Website also notes i.r.o. Phase 1/2 Trial of Oral SRA737 (a Chk1 Inhibitor) Given in Combination with Gemcitabine plus Cisplatin or Gemcitabine Alone in Subjects with Advanced Cancer. - Completed i.r.o GB and 'Prematurely Ended' i.r.o ES.
No way of knowing if in this case 'prematurely ended ' was as a result of positive data leading to fast track or whether Sierra are just not progressing.
https://www.clinicaltrialsregister.eu/ctr-search/search?query=sra737

"Therefore, efforts at identifying safe and effective therapies to prevent COVID from progressing to the moderate and severe disease stages, are critical in the fight against the disease," Professor Nold said.
Bats contract the virus but show minimal disease. The authors say that "preventing progression to severe disease, or effectively treating it—in other words emulating bats—would markedly relieve suffering and save lives."
https://medicalxpress.com/news/2021-09-lessons-resist-covid-treatments-humans.html

Response from Sierra Re SRA737 trials

Hi
As we have said, we are prioritizing our resources on momelotinib right now and are still evaluating potential opportunities for 737. I’ll have to check with our regulatory group regarding the posting of the results on ct.gov.

Regards,
DeDe

From:
Sent: Wednesday, September 15, 2021 12:42 AM
To: DeDe Sheel ; Media Inquiries
Subject: Re: Sierra Oncology to Present at Three September Investor Conferences

CAUTION: This email originated from outside of the organization. Do not click links or open attachments unless you recognize the sender and know the content is safe.

Hi Dede,

As per my previous email, would you kindly confirm the current status and explain the ongoing failure to report on the 2 outstanding trials involving SRA737 within the FDA timescales. https://clinicaltrials.gov/ct2/results?cond=&term=sra737&cntry=&state=&city=&dist=

Kind regards,

China…..

Impatiently waiting for Sierra to publish the long overdue findings of the 2 outstanding trials https://clinicaltrials.gov/ct2/results?cond=&term=SRA737+&cntry=&state=&city=&dist=
In the meantime Gemcitabine seems to be hitting the spot again! https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(21)00404-6/fulltext

Thoth - Sepsis gets a mention in an earlier tweet: https://twitter.com/Sareumplc/status/1252183089067016193?s=20

To be clear, not suggesting for a second that Momly patients shouldn’t receive effective treatment but it needs to be in context.

According to Sierra’s latest Corporate Presentation there are 20,000 patients worldwide who could benefit from Momly. Do we have any idea of how many patients could benefit from SRA737?
Posted yesterday on here https://investor.sierraoncology.com/investor-relations/default.aspx

Thanks Thoth - guess it all depends on what the “experts in the field” advise and what view the bod take to said advice.

Interesting read.
https://www.science.org/content/blog-post/jak-inhibitors-can-t-help-it-bout-shape-i-m
https://twitter.com/jebkeiper/status/1433882628646739968?s=21

https://newsfilter.io/a/812a33d3391053ee7df2d643889f0d5a

BoilB - given the enormity of the implications for Jaks this surely warrants clarification/reassurance from the bod. Furthermore it provides an unmissable opportunity to differentiate Sareum’s Jaks from currently marketed first generation drugs.

The recent Trading Statment notes "...SDC-1801 is now scheduled to commence its final preclinical studies at the beginning of Q4 2021..." Presumably the lead indication will have been determined prior to commencement of the said studies, is that correct? If it is the case then would an RNS not be required to confirm the lead indication given that the potential market size of the chosen target e.g. psoriasis $40b or Lupus $1.8b (https://www.edisongroup.com/publication/treading-the-tyk2-trail/29435/) would have a potentially significant impact on the SP?

The IMC response was to the question 'Could you please confirm the date of the IMC shareholder meeting in respect of Sareum Holdings Trading Statement published on 19th August'.

Good Morning,
No meeting is currently scheduled for Sareum.
Kind Regards,
The Team at Investor Meet Company
W: www.investormeetcompany.com

https://twitter.com/acfer01/status/1428678699650408453?s=21

It is perhaps very telling that against a backdrop of an expressed desire to improve shareholder dialogue and comms that there is, unlike last year, no IMC meeting scheduled in respect of the Trading Update.

Confirmation of final patent issue should come soon....
https://register.epo.org/documentView?number=US.201716343639.A&documentId=1-1-US++1634363916P1+

Not good for either Merck or GSK but may work to our advantage….
https://www.fiercebiotech.com/biotech/merck-s-4-2b-bintrafusp-alfa-nabs-a-3rd-strike-cancer-hopeful-out

https://twitter.com/edison_inv_res/status/1429746628873887747?s=21